An Ottawa tech firm is putting its unique DNA testing capabilities towards detecting early indicators of Alzheimer’s disease.
Spartan Bioscience announced Wednesday a partnership with the Global Alzheimer’s Platform Foundation to help recruit for clinical trials targeting the chronic neurodegenerative disease.
Spartan, known for its distinctive DNA testing cube, has developed a genetic pre-screening test capable of detecting whether subjects carry a particular gene variation that puts them at higher risk of developing Alzheimer’s. According to a release, these individuals might be “ideal clinical trial candidates” for research on the disease.
OBJ360 (Sponsored)
Imagine enjoying a perfectly seared entrée surrounded by Indigenous art and culture, while enjoying breathtaking views of Parliament Hill. Or sipping a glass of wine in a glass-walled space featuring
Imagine enjoying a perfectly seared entrée surrounded by Indigenous art and culture, while enjoying breathtaking views of Parliament Hill. Or sipping a glass of wine in a glass-walled space featuring
Through the announced partnership, Spartan will also contribute $5 from each sale of its pre-screening test towards GAP’s transportation program, which providers Alzheimer’s clinical trial participants with rides to and from their appointments.
Spartan notes that its test is currently cleared for research uses only, not diagnosis.
